Clinical Trials for Childhood Brain Stem Glioma

Trials 1-8 of 8

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Status: Active
Location: 21 locations
Ribociclib and Everolimus Following Radiotherapy in Patients with High-Grade Glioma, and Diffuse Intrinsic Pontine Glioma, Harboring Cell Cycle and/or PI3K/mTOR Pathway Genetic Changes (A TarGeT Treatment Trial)
Status: Active
Location: 6 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 5 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Atovaquone Alone or Combined with Radiation for the Treatment of Children with Malignant Brain Tumors
Status: Active
Location: 2 locations
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 11 locations
Optune Delivered Electric Field Therapy in Treating Children with Recurrent, Progressive, or Refractory High-Grade Glioma or Supratentorial Ependymoma or Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 12 locations